Founder & Director, Chairman & CEO
Dr. Gulati is leading clinical development and the commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock. He has 54 issued patents. He is Professor Emeritus at Midwestern University and is recipient of Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017.
Chief Operating Officer
Mr. Gulati has more than 38 years of experience and knowledge in starting and running medium sized organizations. He is the founding member of Pharmazz India Private Limited and is managing and operating the company since its inception. He was instrumental in initiating and developing a team to conduct all the clinical trials in-house and is extensively involved in selection of sites, the budgetary aspects and legal contracts. Mr. Gulati has provided his expertise to be in full compliance with all related regulatory affairs pertaining to drug development, customs, licensing, FEMA and others.Mr. Gulati has an exceptional ability to create healthy environment for employees.
Executive Vice President
Dr. Reddy has more than 20 years of experience in the biopharmaceutical industry. He has led research and development of products to market success. He managed preclinical development and clinical pharmacology of 4 USFDA approved products. Has a wide range of experience in drug development, including preclinical development, early clinical development, regulatory strategy, intellectual property strategy and technical diligence for licensing. He is an inventor on 17 US patents and has co-authored over 30 peer-reviewed publications.
Formerly, Union Health Secretary, Government of India. Mr. Verma is a very senior administrator with deep experience in the health sector. He was instrumental in formulating and implementing many policies related to the drug development process in India. He also has remarkable interest in literary work.
Vice President and Controller
Mr. Costello brings about 20 years of accounting, budgeting, audit preparation, reporting and financial modeling experience to Pharmazz. He served as Controller for Julian Toft and Downey, Inc. and as Vice President in Transwestern Commercial Real Estate’s Capital Markets Group. Mr. Costello has assisted in the closing of over $500 million in structured finance and equity transactions. Mr. Costello has a CPA designation, earning the Elijah Watts Sells Award for passing with honors, and graduated from Western Illinois University in finance, Magna Cum Laude.
Vice President, Research & Development
Dr. Lavhale has more than twenty years of experience in pre-clinical and clinical development of novel drugs. He did his PhD in Pharmaceutical Sciences and worked for 4 years as a Post-doctoral Fellow at Midwestern University, USA. At Pharmazz he has played a key role in filing several Investigational New Drug Applications in the USA and India. Dr. Lavhale has broad experience in discovery and development of novel first-in-class drug products in critical care medicine. He is an inventor in several issued patents and has more than 40 publications. He received financial grants from UGC, India and was awarded a grant by the NIH, USA.
Director Accounting & Finance
Mr. Bajaj is a Certified Public Accountant having more than 30 years of experience in financial planning and analysis. He has performed financial statement audits and SOX internal control review, facilitated external audit review by big ten auditors. He is specialized in financial and accounting systems of the USA and India with emphasis on pharmaceutical sector.
Assistant Medical Director
Dr. Nitesh P. Tiwari received his MD from King Georges Medical University, Lucknow, India. He has more than fifteen years of experience in clinical practice with a specialization in Critical and Surgical Care. He is actively involved in the clinical development of novel pharmacological agents for the last five years. He is leading a team conducting phase II and III clinical trials and in post-marketing clinical studies. Dr. Tiwari joined Pharmazz in 2020 and is leading the clinical development of centhaquine and sovateltide across multiple indications.